about
Fundamentals of aerosol therapy in critical carePharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamolIssues and challenges in pediatric asthma.Discriminating measures of bronchodilator drug efficacy and potency.Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids.Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate.Emergency pre-hospital management of patients admitted with acute asthmaSelf-management of asthma in general practice, asthma control and quality of life: a randomised controlled trialMeasures for detecting systemic bioactivity with inhaled and intranasal corticosteroids.Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devicesDose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics.Age dependent systemic exposure to inhaled salbutamol.Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children.Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionateShort-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults.House dust mite allergen avoidance and self-management in allergic patients with asthma: randomised controlled trial.Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium.The risk and outcomes of pneumonia in patients on inhaled corticosteroids.Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.In vitro and in vivo testing methods for respiratory drug delivery.Design and application of locally delivered agonists of the adenosine A(2A) receptor.Regulatory toxicology considerations for the development of inhaled pharmaceuticals.Mechanisms of absorption and elimination of drugs administered by inhalation.Lipopolysaccharide challenge: immunological effects and safety in humans.Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide.Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers.Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers.Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation.Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery.Effects of airway calibre on lung delivery of nebulised salbutamol.Cell-based multiscale computational modeling of small molecule absorption and retention in the lungs.Spacer devices increase dose of inhaled corticosteroids deliveredDetermination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.Early bioavailability of inhaled salbutamol reflects lung dose in children.Vitamin A is systemically bioavailable after intratracheal administration with surfactant in an animal model of newborn respiratory distress.Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients.Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers.
P2860
Q28068836-278C14BE-05EC-4612-AB43-0A000ACF5D04Q28363555-D8B6F86F-7004-4B74-B07C-33EDB5F8819BQ34291198-8BCA6F39-C31B-4EEE-AD49-17AF79D9B56BQ34371771-A6D91965-BF66-4436-9059-6002C373B8FBQ35026630-90471F02-DFA2-4697-B7D4-B26935D2038FQ35532795-939DAC74-1235-45EC-848C-6FFDE6F2C7B5Q35533214-5963121A-F3D4-4332-8B2B-BF35E8E57DC2Q35533628-DB3283ED-0B29-4A39-A9DD-C16D399AAED8Q35535414-38D988C4-A056-4D89-AC64-E81EF44E37DFQ35563600-D5531ED7-8273-4E28-BF3C-CC1E255DA9DEQ35803061-69426346-4DED-453A-B21C-3FEB52886ECCQ35827308-683660ED-4CA5-42A7-A53E-7A788E650689Q36024565-6C7887D1-09BB-4A2C-A346-375D25EBFCC9Q36053350-E20B9B6A-10B7-4A2E-B2A0-EB7ABFAE7E9AQ36053634-F570B710-85DF-4323-BCF1-3DE164B12145Q36053825-E962E3ED-A604-46D0-B73A-2398F1130991Q36093451-5AC1EF0B-AD1D-43CB-8AE0-B9727C1014DBQ36924692-9822E55C-9BD3-4D28-AC54-AD62F560BD04Q37077219-26EE1A45-21A0-4044-B4C0-06209B6549B4Q37364624-69D8C7A5-34D2-4FE0-883B-50F1F7730523Q37565681-03F41FC5-5AEB-41F0-B605-DBCD6A677988Q37822755-305C7900-B787-4CDA-A8FA-CACAC30B47B7Q37960072-EDF6C083-75C4-43D1-A5D7-14E253CD402DQ37978447-E5CECF82-694B-4501-AC10-128536F2804CQ38126941-4F096138-1A07-4DD9-869F-A61CF3CC86FDQ38345644-2875149F-2D49-432D-89A6-AF4F34A78515Q38438991-0A6B302E-8725-4285-9D6D-94DE1F9394D2Q38655920-A0436D85-B2BF-4BE2-BD82-507A77109F82Q38856871-9DE445C4-DF08-4B76-A6B7-FF0230EAE36DQ39176996-AA6A11F8-1612-4ECB-A448-FBF088F07416Q39537445-0E5D2CF3-EB8C-435B-906A-B07AB38B9272Q42057923-5C7A5CCE-205B-4B5A-A284-F4AC6204D6A9Q42075969-61B94389-7AED-483A-B095-F2C45C8D3E5FQ42117539-A56E89D4-94D1-479E-97CE-C68661526E93Q42763096-05CECED0-7AAD-4215-A608-F7B7F44003ECQ42858000-3EACA204-AD85-4478-96BA-C574E6DF1DB0Q43112628-DD37C5AF-F12B-4C72-9A48-A85B4382A509Q43136510-71560BEB-FCFE-443D-89BD-2FE01BC38AA5Q43824939-79B6C873-0B8B-47C1-8168-40A63631BBB1Q43900109-697CF01B-D63A-4660-A930-697DED750350
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Pharmacokinetics of inhaled drugs.
@en
type
label
Pharmacokinetics of inhaled drugs.
@en
prefLabel
Pharmacokinetics of inhaled drugs.
@en
P1476
Pharmacokinetics of inhaled drugs.
@en
P2093
Lipworth BJ
P304
P356
10.1046/J.1365-2125.1996.00493.X
P407
P577
1996-12-01T00:00:00Z